JP2021531345A - 腫瘍ワクチン接種に用いるための組合せ製品 - Google Patents

腫瘍ワクチン接種に用いるための組合せ製品 Download PDF

Info

Publication number
JP2021531345A
JP2021531345A JP2021526188A JP2021526188A JP2021531345A JP 2021531345 A JP2021531345 A JP 2021531345A JP 2021526188 A JP2021526188 A JP 2021526188A JP 2021526188 A JP2021526188 A JP 2021526188A JP 2021531345 A JP2021531345 A JP 2021531345A
Authority
JP
Japan
Prior art keywords
polypeptide
tumor
nucleic acid
protein
immune response
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021526188A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021531345A5 (enExample
Inventor
エリック・ハンス・マンティング
サトウィンダー・カウア・シン
アドリアナ・マリア・クライスベーク
ヴィノッド・ソマンダス
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mendus BV
Original Assignee
DCPrime BV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by DCPrime BV filed Critical DCPrime BV
Publication of JP2021531345A publication Critical patent/JP2021531345A/ja
Publication of JP2021531345A5 publication Critical patent/JP2021531345A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/15—Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2021526188A 2018-07-16 2019-07-16 腫瘍ワクチン接種に用いるための組合せ製品 Pending JP2021531345A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP18183694 2018-07-16
EP18183694.1 2018-07-16
EP19170999.7 2019-04-25
EP19170999 2019-04-25
PCT/NL2019/050451 WO2020017962A1 (en) 2018-07-16 2019-07-16 A combination product for use in tumor vaccination.

Publications (2)

Publication Number Publication Date
JP2021531345A true JP2021531345A (ja) 2021-11-18
JP2021531345A5 JP2021531345A5 (enExample) 2022-07-12

Family

ID=67544309

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021526188A Pending JP2021531345A (ja) 2018-07-16 2019-07-16 腫瘍ワクチン接種に用いるための組合せ製品

Country Status (5)

Country Link
US (2) US11071778B2 (enExample)
EP (1) EP3823668A1 (enExample)
JP (1) JP2021531345A (enExample)
CA (1) CA3104833A1 (enExample)
WO (1) WO2020017962A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110891602A (zh) 2017-06-23 2020-03-17 帕多瓦有限责任公司 嵌合病毒样颗粒以及其作为免疫反应的抗原特异性重定向剂的用途
CA3104833A1 (en) 2018-07-16 2020-01-23 Dcprime B.V. A combination product for use in tumor vaccination.
JP7641005B2 (ja) 2018-12-27 2025-03-06 ヴェリミューン インコーポレイテッド コンジュゲート型ウイルス様粒子および抗腫瘍免疫リダイレクタとしてのその使用
US11052144B2 (en) 2019-04-25 2021-07-06 Dcprime B.V. Methods of tumor vaccination
US12091681B2 (en) 2020-03-27 2024-09-17 Mendus B.V. Ex vivo use of modified cells of leukemic origin for enhancing the efficacy of adoptive cell therapy
CA3172447A1 (en) * 2020-03-27 2021-09-30 Erik Hans MANTING In vivo use of modified cells of leukemic origin for enhancing the efficacy of adoptive cell therapy
WO2022003568A1 (en) * 2020-06-30 2022-01-06 Dcprime B.V. Use of leukemia-derived cells in ovarian cancer vaccines
MX2023004465A (es) 2020-10-19 2023-06-19 Verimmune Inc Composiciones basadas en virus y métodos para redirigir respuestas inmunitarias preexistentes mediante su uso para el tratamiento del cáncer.
US20220168407A1 (en) * 2020-11-05 2022-06-02 Dcprime B.V. Use of tumor-independent antigens in immunotherapies
KR20230135075A (ko) 2021-01-22 2023-09-22 멘두스 비.브이. 종양 백신접종 방법
WO2024197451A1 (en) * 2023-03-24 2024-10-03 Virogin Biotech (Shanghai) Ltd. Homologous and heterologous therapeutic vaccination strategies for cancer treatment

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014513072A (ja) * 2011-04-07 2014-05-29 アントネッロ ペッシ 腫瘍特異的な細胞表面受容体を認識する抗体に融合された非自己ｔ細胞エピトープおよびその使用
WO2017077275A1 (en) * 2015-11-02 2017-05-11 Imperial Innovations Limited Phagemid vector

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO180167C (no) 1994-09-08 1997-02-26 Photocure As Fotokjemisk fremgangsmåte til å innföre molekyler i cellers cytosol
US5667786A (en) 1995-06-07 1997-09-16 Novavax, Inc. Method for treating tumors with a toxin
GB9905911D0 (en) 1999-03-15 1999-05-05 Photocure As Method
EP1246646A2 (en) 2000-01-05 2002-10-09 Aventis Pasteur Limited Enhancing the immune response to an antigen by presensitizing with an inducing agent prior to immunizing with the inducing agent and the antigen
US7118740B1 (en) * 2000-09-22 2006-10-10 Mayo Foundation For Medical Education And Research Method for limiting the growth of cancer cells using an attenuated measles virus
EP1346059B1 (en) 2000-11-29 2012-05-23 PCI Biotech AS Photochemical internalization for delivery of molecules into the cytosol
AU2210402A (en) 2000-11-29 2002-06-11 Norwegian Radium Hospital Res Photochemical internalization for virus-mediated molecule delivery into the cyosol
ES2399386T3 (es) 2001-04-05 2013-04-01 Novartis Vaccines And Diagnostics, Inc. Aumento de la inmunidad de las mucosas tras sensibilización parenteral
GB0121023D0 (en) 2001-08-30 2001-10-24 Norwegian Radium Hospital Res Compound
US20040057935A1 (en) 2002-09-20 2004-03-25 Cedars-Sinai Medical Center Intratumoral delivery of dendritic cells
JP2006232761A (ja) 2005-02-25 2006-09-07 Osaka Univ 制癌剤
WO2006137398A1 (ja) 2005-06-21 2006-12-28 The Research Foundation For Microbial Diseases Of Osaka University 癌治療薬
PT2201100E (pt) 2007-09-14 2016-06-03 Univ Brussel Vrije Aperfeiçoamento da capacidade estimulatória de células t das células que apresentam antígeno humano e o seu uso na vacinação
US20110110979A1 (en) 2008-04-16 2011-05-12 Universite De Lausanne Method and vaccine for optimizing the specific immune responses
AU2008285598B2 (en) 2008-05-19 2015-04-16 Dcprime B.V. Method for inducing and accelerating cells
GB0914286D0 (en) 2009-08-14 2009-09-30 Pci Biotech As Method
IL224940A (en) 2010-09-02 2017-06-29 Scripps Research Inst Providing a drug for growth based on nanoparticles
NL2009102C2 (en) 2012-07-02 2014-01-06 Dcprime B V Method for dc-loading.
EP2743344A1 (en) 2012-12-11 2014-06-18 DCPrime B.V. Therapeutic cancer vaccines derived from a novel dendritic cell line
WO2014138314A1 (en) 2013-03-05 2014-09-12 Baylor College Of Medicine Oncolytic virus
WO2015073801A1 (en) 2013-11-14 2015-05-21 Duke University Tetanus toxoid and ccl3 improve dc vaccines
JP2019526274A (ja) * 2016-07-21 2019-09-19 ヴァック４オール・ピーティーイー・リミテッドＶａｃ４Ａｌｌ Ｐｔｅ． Ｌｔｄ． 抗マラリアワクチンとしてのバイオ融合タンパク質
CA3104833A1 (en) 2018-07-16 2020-01-23 Dcprime B.V. A combination product for use in tumor vaccination.

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014513072A (ja) * 2011-04-07 2014-05-29 アントネッロ ペッシ 腫瘍特異的な細胞表面受容体を認識する抗体に融合された非自己ｔ細胞エピトープおよびその使用
WO2017077275A1 (en) * 2015-11-02 2017-05-11 Imperial Innovations Limited Phagemid vector

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ANTICANCER RESEARCH, vol. 16, JPN6023031607, 1996, pages 2105 - 2110, ISSN: 0005275418 *

Also Published As

Publication number Publication date
EP3823668A1 (en) 2021-05-26
US20200397883A1 (en) 2020-12-24
WO2020017962A1 (en) 2020-01-23
US20220023406A1 (en) 2022-01-27
CA3104833A1 (en) 2020-01-23
US11071778B2 (en) 2021-07-27

Similar Documents

Publication Publication Date Title
US11071778B2 (en) Combination product for use in tumor vaccination
JP6373836B2 (ja) 多量体融合タンパク質ワクチン及び免疫療法
US11052144B2 (en) Methods of tumor vaccination
EP3758747A1 (en) Self-asssembling nanostructure vaccines
CN113151184A (zh) 基于细胞膜展示冠状病毒免疫原以诱导中和抗体的方法
JP4210519B2 (ja) 低免疫原性抗原の免疫原性を増強する医薬組成物
TW202206598A (zh) 對抗ＳＡＲＳ－ＣｏＶ－２之疫苗及其製品
JP2022046617A (ja) 異種ポリペプチドを含むＣｙａＡベースのキメラタンパク質及び免疫応答の誘導におけるその使用
JP2004523494A6 (ja) 低免疫原性抗原の免疫原性を増強する医薬組成物
WO2023052600A1 (en) Methods and particles for modulating an immune response
US11186618B2 (en) Dendritic-cell-targeted peptide, fusion peptide utilizing said peptide, and vaccine utilizing said fusion peptide
TW202506174A (zh) 一種針對ＭＩＣＡ／Ｂ靶點的ｍＲＮＡ腫瘤疫苗
CN114269792B (zh) 稳定的嵌合合成蛋白及其治疗用途
US20250101128A1 (en) Chimeric polypeptide compositions and encoding polynucleotides thereof
CN121518519A (zh) 多价猪圆环病毒疫苗
김형윤 Development of Human Papillomavirus (HPV) Vaccine Using Human Cysteinyl-tRNA Synthetase 1 and Tumor Antigens
EP4580672A1 (en) Nanoparticle-derived vaccines against poxviruses, and methods for making and using the same

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220704

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220704

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230808

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20231107

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20240305